Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models

BACKGROUND: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Surg Open Sci
Main Authors: Rios Perez, Mayrim V., Roife, David, Dai, Bingbing, Pratt, Michael, Dobrowolski, Ryszard, Kang, Ya'an, Li, Xinqun, Augustine, Jithesh J., Zielinski, Rafal, Priebe, Waldemar, Fleming, Jason B.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083010/
https://ncbi.nlm.nih.gov/pubmed/33981979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.sopen.2019.05.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares